Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
This article was originally published in The Pink Sheet Daily
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.
You may also be interested in...
Triumphant in Europe at the regulatory stage, Alimera finds that health technology assessment is a different ball game, as NICE turns down Iluvien for diabetic macular edema on two counts.
The Institute for Clinical and Economic Review conducted a technology assessment for anti-VEGF agents in diabetic macular edema for CMS in preparation for an upcoming MedCAC review.
NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting